Immunohistochemistry (IHC)
A test that uses antibodies to mark specific proteins in tumour tissue.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Purpose of the test
- Determining the origin of tumor cells.
- Assess markers such as CD20, CD30, CD19, or HER2.
Informs decisions
- Classification of tumor types and subtypes.
- Relevant therapeutic categories to discuss.
How the test is done
Special staining of tissue sections that have been processed in the pathology laboratory.
- Sample type
- Block tumor tissue
- Estimated result time
- Generally several working days.
Limitations
- Results depend on the quality and age of the tissue blocks.
- Laboratory standards and internal controls are needed.
- Some markers may change after previous therapy.
Related
Cancer types
Not displayed
TanyaKanker does not display test-cost estimates. Ask the laboratory or facility providing the test for cost details directly.
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
To check
- Liver Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Colorectal Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Stomach Cancer
Subtype
Reason: Memerlukan pemeriksaan
- CAR-T (chimeric antigen receptor T-cell therapy)
Treatment category
Reason: Memerlukan pemeriksaan
- Targeted therapy
Treatment category
Reason: Memerlukan pemeriksaan
- BCMA
Biomarker
Reason: Diperiksa melalui
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.